GLB 2002
Alternative Names: AAV8.pTHVE002Latest Information Update: 21 May 2021
At a glance
- Originator GeneLeap Biotech
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 14 May 2021 Preclinical trials in Wet age-related macular degeneration in USA (unspecified route) as of May 2021 (Company pipeline May 2021)